{"id":9739,"date":"2024-01-19T23:56:00","date_gmt":"2024-01-19T15:56:00","guid":{"rendered":"https:\/\/flcube.com\/?p=9739"},"modified":"2024-10-27T00:07:46","modified_gmt":"2024-10-26T16:07:46","slug":"lees-pharmaceutical-to-develop-windtrees-cardiovascular-drugs-in-greater-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=9739","title":{"rendered":"Lee\u2019s Pharmaceutical to Develop Windtree\u2019s Cardiovascular Drugs in Greater China"},"content":{"rendered":"\n

Lee\u2019s Pharmaceutical Ltd (HKG: 0950<\/a>) has entered into a licensing agreement with US-based Windtree Therapeutics Inc., (NASDAQ: WINT<\/a>) to develop and commercialize multiple cardiovascular disease (CVD) treatments in the Greater China region. The agreement includes the development of istaroxime, a Phase III-ready, first-in-class dual-mechanism SERCA2a activator for acute heart failure and cardiogenic shock, as well as Windtree\u2019s next-generation SERCA2a activators in the preclinical stage. Additionally, the deal encompasses rostafuroxin, a digitoxigenin analog designed to reduce hypertension in patients with specific genotypes.<\/p>\n\n\n\n

Under the terms of the agreement, Lee\u2019s has committed to milestone payments of up to USD 138.1 million, with USD 100 million allocated to the performance of the SERCA2a activators in heart failure treatments. Windtree is also entitled to receive low double-digit royalties on any future sales of the products in the region.<\/p>\n\n\n\n

This new deal builds upon an existing partnership between Windtree and Lee\u2019s. In 2017, Windtree licensed three of its KL4 surfactant respiratory product candidates and aerosolization technologies to Lee\u2019s. Istaroxime, originally discovered by Italy-based Sigma-Tau, now Leadiant Biosciences, was sold to Taiwan\u2019s CVie Therapeutics in 2012. Following CVie\u2019s merger with Windtree in 2018, the molecule has been further developed as a positive inotropic agent that enhances myocardial contractility. Istaroxime has shown significant improvements in cardiac function and blood pressure without increasing heart rate or the risk of cardiac rhythm disturbances in Phase II studies, including those involving Chinese patients. Lee\u2019s will now independently fund and conduct a Phase III trial in China while Windtree continues its global development program.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Lee\u2019s Pharmaceutical Ltd (HKG: 0950) has entered into a licensing agreement with US-based Windtree Therapeutics…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[69,941,165,1631,25,1632],"class_list":["post-9739","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-cvd","tag-hkg-0950","tag-lees-pharmaceutical","tag-nasdaq-wint","tag-potential-first-in-class","tag-windtree-therapeutics"],"yoast_head":"\nLee\u2019s Pharmaceutical to Develop Windtree\u2019s Cardiovascular Drugs in Greater China - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Lee\u2019s Pharmaceutical Ltd (HKG: 0950) has entered into a licensing agreement with US-based Windtree Therapeutics Inc., (NASDAQ: WINT) to develop and commercialize multiple cardiovascular disease (CVD) treatments in the Greater China region. The agreement includes the development of istaroxime, a Phase III-ready, first-in-class dual-mechanism SERCA2a activator for acute heart failure and cardiogenic shock, as well as Windtree\u2019s next-generation SERCA2a activators in the preclinical stage. Additionally, the deal encompasses rostafuroxin, a digitoxigenin analog designed to reduce hypertension in patients with specific genotypes.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=9739\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lee\u2019s Pharmaceutical to Develop Windtree\u2019s Cardiovascular Drugs in Greater China\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=9739\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-01-19T15:56:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-26T16:07:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=9739#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=9739\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Lee\u2019s Pharmaceutical to Develop Windtree\u2019s Cardiovascular Drugs in Greater China\",\"datePublished\":\"2024-01-19T15:56:00+00:00\",\"dateModified\":\"2024-10-26T16:07:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=9739\"},\"wordCount\":273,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CVD\",\"HKG: 0950\",\"Lee's Pharmaceutical\",\"NASDAQ: WINT\",\"Potential first-in-class\",\"Windtree Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=9739#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=9739\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=9739\",\"name\":\"Lee\u2019s Pharmaceutical to Develop Windtree\u2019s Cardiovascular Drugs in Greater China - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-01-19T15:56:00+00:00\",\"dateModified\":\"2024-10-26T16:07:46+00:00\",\"description\":\"Lee\u2019s Pharmaceutical Ltd (HKG: 0950) has entered into a licensing agreement with US-based Windtree Therapeutics Inc., (NASDAQ: WINT) to develop and commercialize multiple cardiovascular disease (CVD) treatments in the Greater China region. The agreement includes the development of istaroxime, a Phase III-ready, first-in-class dual-mechanism SERCA2a activator for acute heart failure and cardiogenic shock, as well as Windtree\u2019s next-generation SERCA2a activators in the preclinical stage. Additionally, the deal encompasses rostafuroxin, a digitoxigenin analog designed to reduce hypertension in patients with specific genotypes.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=9739#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=9739\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=9739#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lee\u2019s Pharmaceutical to Develop Windtree\u2019s Cardiovascular Drugs in Greater China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lee\u2019s Pharmaceutical to Develop Windtree\u2019s Cardiovascular Drugs in Greater China - Insight, China's Pharmaceutical Industry","description":"Lee\u2019s Pharmaceutical Ltd (HKG: 0950) has entered into a licensing agreement with US-based Windtree Therapeutics Inc., (NASDAQ: WINT) to develop and commercialize multiple cardiovascular disease (CVD) treatments in the Greater China region. The agreement includes the development of istaroxime, a Phase III-ready, first-in-class dual-mechanism SERCA2a activator for acute heart failure and cardiogenic shock, as well as Windtree\u2019s next-generation SERCA2a activators in the preclinical stage. Additionally, the deal encompasses rostafuroxin, a digitoxigenin analog designed to reduce hypertension in patients with specific genotypes.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=9739","og_locale":"en_US","og_type":"article","og_title":"Lee\u2019s Pharmaceutical to Develop Windtree\u2019s Cardiovascular Drugs in Greater China","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=9739","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-01-19T15:56:00+00:00","article_modified_time":"2024-10-26T16:07:46+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=9739#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=9739"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Lee\u2019s Pharmaceutical to Develop Windtree\u2019s Cardiovascular Drugs in Greater China","datePublished":"2024-01-19T15:56:00+00:00","dateModified":"2024-10-26T16:07:46+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=9739"},"wordCount":273,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CVD","HKG: 0950","Lee's Pharmaceutical","NASDAQ: WINT","Potential first-in-class","Windtree Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=9739#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=9739","url":"https:\/\/flcube.com\/?p=9739","name":"Lee\u2019s Pharmaceutical to Develop Windtree\u2019s Cardiovascular Drugs in Greater China - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-01-19T15:56:00+00:00","dateModified":"2024-10-26T16:07:46+00:00","description":"Lee\u2019s Pharmaceutical Ltd (HKG: 0950) has entered into a licensing agreement with US-based Windtree Therapeutics Inc., (NASDAQ: WINT) to develop and commercialize multiple cardiovascular disease (CVD) treatments in the Greater China region. The agreement includes the development of istaroxime, a Phase III-ready, first-in-class dual-mechanism SERCA2a activator for acute heart failure and cardiogenic shock, as well as Windtree\u2019s next-generation SERCA2a activators in the preclinical stage. Additionally, the deal encompasses rostafuroxin, a digitoxigenin analog designed to reduce hypertension in patients with specific genotypes.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=9739#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=9739"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=9739#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Lee\u2019s Pharmaceutical to Develop Windtree\u2019s Cardiovascular Drugs in Greater China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/9739","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=9739"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/9739\/revisions"}],"predecessor-version":[{"id":9740,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/9739\/revisions\/9740"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=9739"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=9739"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=9739"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}